Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> Deubiquitinase>>XL177A

XL177A

Catalog No.GC62517

XL177A es un inhibidor irreversible de USP7 muy potente y selectivo con una IC50 de 0,34nM. XL177A provoca la muerte de células cancerosas a través de un mecanismo dependiente de p53.

Products are for research use only. Not for human use. We do not sell to patients.

XL177A Chemical Structure

Cas No.: 2417089-74-6

Tamaño Precio Disponibilidad Cantidad
5 mg
216,00 $
Disponible
10 mg
342,00 $
Disponible
25 mg
684,00 $
Disponible
50 mg
1.089,00 $
Disponible
100 mg
1.800,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

XL177A is a highly potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. XL177A elicits cancer cell killing through a p53-dependent mechanism[1].

XL177A is a potent USP7 inhibitor and p53 stabilizer in cyto. XL177A suppresses cancer cell growth predominantly through a p53-dependent mechanism. XL177A labels the catalytic cysteine, C223, of USP7 with exquisite selectivity for USP7 across the DUBome and human proteome[1]. XL177A (1 μM) induces complete G1 arrest in MCF7 cells after 24 hours[1].Treatment of MCF7 cells, which express WT TP53, with XL177A (0.001- 10 μM) induces rapid degradation of HDM2 within 2 hours, followed by increases in p53 and downstream p21 protein levels[1].

[1]. Nathan J Schauer, et al. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep.2020 Mar 24;10(1):5324.

Reseñas

Review for XL177A

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for XL177A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.